===Figure Technology Solutions (FIGR) reported earnings on Thur 13 Aug 2026 (b/o)

 

Figure Technology Solutions Q2 2026 non-GAAP EPS $0.35 (+150% YoY) and revenue $225.6M (+102% YoY) beat estimates as Connect mix boosts margins

• Investor Takeaway: Strong volume and revenue beat with expanding margins as capital-light Connect scales rapidly.
• Biggest Positive: Figure Connect now 65% of volume, driving 55% adjusted EBITDA margin and capital efficiency.
• Biggest Risk: Take rate at 3.6% pressured by faster-than-expected mix shift and rate volatility.
• Key Results: $4.3B CLM volume (+132% YoY, 4% above guidance top), $218M adjusted net revenue (+95%).
• Profitability: Net income $87M (+190% YoY); adjusted EBITDA $119M (+126%), 55% margin despite 1.7-point Democratized Prime drag.
• Guidance: Q3 CLM volume $4.8–5.2B (midpoint $5B); management "feels very strongly confident" based on July seasonality.
• Growth Drivers: HELOC-led demand, new SMB/home improvement verticals, 489 partners (+102 QoQ), Democratized Prime third-party assets $170M.
• Problem Areas: Take rate expected to stay near low end of 3.5–4% range; interest-rate moves hurt gain-on-sale.
• Balance Sheet & Capital: $1.44B cash; $600M 8.5% senior notes fund Kiavi deal and broaden funding access.

==AbCellera (ABCL) : Positive Hot-Flash Drug Trial Results

 

(Bloomberg) -- Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial.

"We believe ABCL635 has potential to be a blockbuster product," Chief Executive Officer Carl Hansen told investors on a Monday conference call. "The efficacy data is beyond even the most aggressive upside scenario we had dared to consider."

The drug aims to block a biological signal associated with hot flashes, which can cause sudden feelings of uncomfortable heat and disruption to sleep. Hansen said it has significant market potential because it would be a non-hormonal treatment, and the hormone therapies currently available are unsuitable for 20% of women.

The company said its experimental shot reduced the frequency and severity of hot flashes over a four-week study period compared with a placebo, with no serious side effects. The most common side effects patients getting the drug experienced were headaches, fatigue and injection-site reactions.

AbCellera went public in December 2020 and played a role in the development of a Covid-19 therapy. The company was backed at an earlier stage by billionaire Palantir Technologies Inc. co-founder Peter Thiel, and he also sat on its board. Thiel stepped down from that role in 2024.

Earnings this week : Aug 10 - 14, 26 (wk 33)

 

Monday (Aug 10)

• Morning: ACH AIOT AIRS AXSM B BBGI BBRK-B BTDR CAMT CECO CEVA CMCL CNDT CRC DOLE EEMBJ EMBJ FERG FSTR GCMG HRTX INSW INTT JRSH KEEL KSPI LIF LINC MITT MNDY MPAA MPT NABL NESR NIU NYAX OPAL PERI POWW QTRX RDNT SBET SDRL SGRY SNDA SOHU TH TLS TNXP VERU VFF
• Afternoon: AAON ACHR ACM ACVA ALC ALCO ALMR ALTI AMTM APEI AREN ARQ ASTS AVD BBIO BCSF BKD BKKT BNGO BODI BW BWMN CATX CBLL CCAP CHMI CNNE CODI DH DJT DMAC DPRO DSP ENTA EROK EVC EXOD FF FLNT GAIA GCTS GENK GETY GPRO GUTS HFFG HIMS HLIO HNRG HPK HQI HROW IAUX IHRT IMDX INR JBS JRVR KBDC MG MLAB MVST NGS NHI NIQ NUS OPFI PAL PANL PFLT PIII PLBY PLUG PNNT PPHC PRPL QMCO QUBT RDVT RKLB RPAY RPD RUM SCM SHIM SMC SPG SRFM SUPV SVM TCMD TELA TISI TTEC UPWK URG USAR VREX WBTN

Tuesday (August 11)

• Morning: ARMK CAH CDNL NVRI ETOR JBI LEGN MIDD ONON SE SFD TME VG
• Afternoon: ABSI AGRO AII AQST ATEX ATRO BGS BORR BRCB CAVA CINT CRWV DDI DNN EROC EVLV FAC FLY FNV FTW HRB HYLN IFS IMOS ITRG LAND LIF LITE MLYS MOBI NCMI NN NRGV QNT QUIK RDNW SMCI TSHA UAMY VELO VINP

Wednesday (August 12) 

• Morning: AMCR BETA EAT FRVO GLBE KTB KRNT LQDA MSGE MRX EYE NBIS PFGC WYFI
• Afternoon: ALLO ANDG AOSL AVEX AVIR AZ BTGO CAE CBRS CEPL COHR CSCO CURI DERM DFDV EARN ENS ENVX EPSN EQPT FOSL FWDI GO HDRN HLIT INFQ ITG JACK KE KURA LFTO LMRI LPA MPTI MXCT NNE NOA OMER OPRX PAAS PARK PLGO REZI RRGB SCOR SECZ SID SKYH SKYX SPCE SPIR SSMR STAA STN STUB SUZ TBBB VOR WATT WHK

Thursday (August 13)

• Morning: ABEO AEBI AIRO AIT ALH ARCO ARX ASND AVAH BIRK BKTI BLSH BLTE BN BSP BTBT CLBT CRMD DDS ECC EIC ELMT ESEA EVO EVT FIGR FRMI GDS GLNG GMRS GWRS IDR ISSC JD LAC LGN LUNR LWAY MH MLCO MSC MSGS MWH NFGC NOMD ONDS POET PRQR PSFE PSUS SBC SNFCA SSYS TPR TSAT VALN WWW XE XNET YETI YSWY
• Afternoon: ACOG AEYE AIRJ AMAT AMPG API BAP BOF BZAI CAPR CBUS CELC CNVS CV DEFT DLO DMRC ENHA ETON FIRY FOCL FTLF GEMI GLAS GLOB GNSS GRSD HAWK HIT HTFL ICCC IDN INV JCAP KLC KULR MOB MRLN NKTR NMAX NPWR NU NXB PED PEW PMN QSI REKR ROC SLNH SPRY SSTI STNE SWMR TMC TSSI VERI VUZI WYY YSS

Friday (August 14)

• Morning: ACXP AMSS BKYI BRUN CSPI DGXX DTST EDBL LFWD LNZA LTRN MLSS OBAI OTLK PAVM PWCM QNRX RIME RLX RMIX SIND SLE STRR TMS USAS VNRX
• Afternoon: None

==Loma Negra (LOMA) reported earnings on Thur 6 Aug 26 (b/o)

Loma Negra Compania Industrial Argentina Sociedad Anonima ADR reports Q2 results with non-GAAP EPS $0.01 (+1620% YoY) on revenue $159.1M (+21% YoY), EPS misses, revenue beats

• 2Q26 net profit jumped to Ps. 7.0 billion as net sales grew 2.1% YoY to Ps. 238.1 billion.
• Adjusted EBITDA declined 2.5% in 2Q26 to Ps. 48.2 billion.

BackgroundFounded in 1926, Loma Negra is Argentina’s top cement, masonry cement, aggregates, concrete, and lime producer (market share around 45% at the time). It was controlled by Brazil’s InterCement (part of Camargo Correa) before the IPO. Proceeds primarily went to the parent for debt reduction, with some used for capacity expansion (e.g., the L’Amali plant).

 

Loma Negra C.I.A.S.A. (NYSE: LOMA; BYMA: LOMA), Argentina’s leading cement producer, completed its IPO in late October/early November 2017.